Efficacy News and Research

RSS

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

Biomedical Systems launches wireless ambulatory ECG monitoring system for management of AF

Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia.

19 Mar 2012

Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

arGEN-X introduces NHance technology to create therapeutic antibodies

arGEN-X announces today the launch of NHance, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

19 Mar 2012

HemCon disappointed with CAFC decision over Marine Polymer patent infringement case

HemCon Medical Technologies, Inc. announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued an en banc decision on March 15, 2012 in the 2006 patent infringement case brought by Marine Polymer Technologies Inc. The decision affirmed a trial court decision awarding damages to Marine Polymer and enjoining the manufacture of infringing products.

17 Mar 2012

Researchers report higher price tag for robotic prostatectomy surgery

In perfecting the science of medicine, advancements always face exhaustive scrutiny and opposition. Typically, these rigors focus on confirming the efficacy of a procedure or treatment to ensure it remains in the patient's best interest for healing or wellness. More recently, with heightened emphasis on government-funded healthcare, medical procedures such as robotic prostatectomy surgery for prostate cancer treatment are under fire for cost.

17 Mar 2012

Sanofi enters definitive agreement to acquire Pluromed

Sanofi and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

17 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

Kips Bay Medical fourth quarter net sales decrease to $94,000

Kips Bay Medical, Inc. today announced financial results for fourth quarter and year ended December 31, 2011.

17 Mar 2012

Gates Foundation grants biotech firm Aeras $220 million over 5 years to develop TB vaccines

The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15).

17 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

CCN1 protein orchestrates cellular antiviral response in the extracellular matrix

Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

16 Mar 2012

FDA clears Alma Lasers' novel approach for treatment of nail fungus

For the 35 million people worldwide that suffer from Onychomycosis (nail fungus), a new, fast, effective approach to treatment is now available. Alma Lasers, Inc., a leader in laser, light, radiofrequency and ultrasound aesthetic and medical devices, is pleased to announce the introduction of its newest innovation for the Harmony(XL) multi-application, multi-technology platform, a novel approach for the treatment of nail fungus.

16 Mar 2012

Longer looks: Last interview with Oregon's assisted-suicide law architect; Med students spurn primary care for hospital jobs

Dr. Peter Goodwin, a family physician and right-to-die activist, took his own life on March 11, 2012, at age 83. He did it legally, with the blessing of his family and doctors, under the Oregon law allowing physician-assisted suicide - the first such law in the country - that Goodwin was instrumental in creating. … He did not look like a dying man; he was chirpy and alert ... However, as a result of his fatal disease - a Parkinsons-like condition called coritcobasal degeneration - he could not use his right hand or do much reliably with his left.

16 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

Efficacy News and Research

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Biomedical Systems launches wireless ambulatory ECG monitoring system for management of AF

Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

arGEN-X introduces NHance technology to create therapeutic antibodies

HemCon disappointed with CAFC decision over Marine Polymer patent infringement case

Researchers report higher price tag for robotic prostatectomy surgery

Sanofi enters definitive agreement to acquire Pluromed

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Kips Bay Medical fourth quarter net sales decrease to $94,000

Gates Foundation grants biotech firm Aeras $220 million over 5 years to develop TB vaccines

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

Tarsa advances OSTORA NDA filing through $28M Series B financing

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

CCN1 protein orchestrates cellular antiviral response in the extracellular matrix

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

FDA clears Alma Lasers' novel approach for treatment of nail fungus

Longer looks: Last interview with Oregon's assisted-suicide law architect; Med students spurn primary care for hospital jobs

Shire enters agreement to acquire FerroKin BioSciences

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News